Citigroup
BIB icon

Citigroup’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Citigroup’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-120
Closed -$5K – 7666
2019
Q3 		$5K Hold
120
– – ﹤0.01% 7316
2019
Q2 		$6K Buy
+120
New +$5.97K ﹤0.01% 7426
2014
Q3 		– Sell
-8,528
Closed -$396K – 7060
2014
Q2 		$396K Buy
8,528
+6,680
+361% +$264K ﹤0.01% 3616
2014
Q1 		$74K Buy
+1,848
New +$83.9K ﹤0.01% 5227

Other funds holding BIB

GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
SW
SkyOak Wealth Southfield, Michigan $546M AUM 18.14% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

Citigroup's BIB Position: Q4 2019 in Review

Citigroup sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2019, closing a stake of 120 shares — an estimated $5K sold.

Citigroup first reported a position in BIB in Q1 2014 and held it in 4 quarters. The position peaked at $396K in Q2 2014. 26 funds tracked by Wall St. Rank hold BIB as of Q4 2019.

  • Citigroup reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Citigroup sold 120 ProShares Ultra NASDAQ Biotechnology shares in Q4 2019, an estimated $5K.
  • Citigroup first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 4 quarters.
  • Citigroup's ProShares Ultra NASDAQ Biotechnology position peaked at $396K in Q2 2014.
  • 26 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2019.

Based on Citigroup's 13F filing for Q4 2019, filed 12 Feb 2020.